Comparison · NCT03633344-a87502b2
Carbowhite vs Carbowhite Placebo: Reduction in Frequency of Defecation to 3 Times Per Day
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Carbowhite vs Carbowhite Placebo: Reduction in Frequency of Defecation to 3 Times Per Day. Trial comparisons, record NCT03633344-a87502b2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03633344-a87502b2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.983 | 0.941 | 0.995 | wilson | |
| Risk in group 2 | 1 | 0.862 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0167 | -0.0587 | 0.122 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.983 | 0.961 | 1.01 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Carbowhite than on Carbowhite Placebo | 60 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Carbowhite | 3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)~Carbowhite | 118 | 120 | OG000 |
| Group 2 | Carbowhite Placebo | 3 tablets as a single dose (210 mg х 3 = 630 mg) t.i.d. (630 mg х 3 = 1,890 mg) | 24 | 24 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Reduction in Frequency of Defecation to 3 Times Per Day
- Description
- Percent of patients administered the investigational production who achieved the efficacy endpoint (reduction in frequency of defecation to 3 times per day, absence of loose stool) on Day 5 or earlier
- Time frame
- From randomisation up to 5 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form in Patients With Acute Diarrhea
- NCT number
- NCT03633344
- Phases
- PHASE2
- Conditions
- Diarrhoea;Acute
- Interventions
- Carbowhite, Carbowhite placebo
- Lead sponsor
- Omnifarma Kiev LLC
- Results first posted
- 2019-06-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03633344?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03633344-a87502b2